Harnessing the immune system to overcome cytokine storm and reduce viral load in COVID-19: a review of the phases of illness and therapeutic agents.
Antiviral Agents
/ therapeutic use
Betacoronavirus
/ isolation & purification
COVID-19
COVID-19 Testing
Child
Clinical Laboratory Techniques
Coronavirus Infections
/ diagnosis
Cytokines
/ immunology
Humans
Immunity, Innate
/ immunology
Pandemics
Pneumonia, Viral
/ diagnosis
SARS-CoV-2
Viral Load
COVID-19 Drug Treatment
Acute respiratory distress syndrome
Angiotensin converting enzyme 2
Antiviral
COVID-19
Chloroquine
Cytokine release syndrome
Immunotherapy
Pathophysiology
SARS-CoV-2
Tocilizumab
Journal
Virology journal
ISSN: 1743-422X
Titre abrégé: Virol J
Pays: England
ID NLM: 101231645
Informations de publication
Date de publication:
15 10 2020
15 10 2020
Historique:
received:
20
04
2020
accepted:
18
09
2020
entrez:
16
10
2020
pubmed:
17
10
2020
medline:
6
11
2020
Statut:
epublish
Résumé
Coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2, previously named 2019-nCov), a novel coronavirus that emerged in China in December 2019 and was declared a global pandemic by World Health Organization by March 11th, 2020. Severe manifestations of COVID-19 are caused by a combination of direct tissue injury by viral replication and associated cytokine storm resulting in progressive organ damage. We reviewed published literature between January 1st, 2000 and June 30th, 2020, excluding articles focusing on pediatric or obstetric population, with a focus on virus-host interactions and immunological mechanisms responsible for virus associated cytokine release syndrome (CRS). COVID-19 illness encompasses three main phases. In phase 1, SARS-CoV-2 binds with angiotensin converting enzyme (ACE)2 receptor on alveolar macrophages and epithelial cells, triggering toll like receptor (TLR) mediated nuclear factor kappa-light-chain-enhancer of activated B cells (NF-ƙB) signaling. It effectively blunts an early (IFN) response allowing unchecked viral replication. Phase 2 is characterized by hypoxia and innate immunity mediated pneumocyte damage as well as capillary leak. Some patients further progress to phase 3 characterized by cytokine storm with worsening respiratory symptoms, persistent fever, and hemodynamic instability. Important cytokines involved in this phase are interleukin (IL)-6, IL-1β, and tumor necrosis factor (TNF)-α. This is typically followed by a recovery phase with production of antibodies against the virus. We summarize published data regarding virus-host interactions, key immunological mechanisms responsible for virus-associated CRS, and potential opportunities for therapeutic interventions. Evidence regarding SARS-CoV-2 epidemiology and pathogenesis is rapidly evolving. A better understanding of the pathophysiology and immune system dysregulation associated with CRS and acute respiratory distress syndrome in severe COVID-19 is imperative to identify novel drug targets and other therapeutic interventions.
Sections du résumé
BACKGROUND
Coronavirus disease 2019 (COVID-19) is caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2, previously named 2019-nCov), a novel coronavirus that emerged in China in December 2019 and was declared a global pandemic by World Health Organization by March 11th, 2020. Severe manifestations of COVID-19 are caused by a combination of direct tissue injury by viral replication and associated cytokine storm resulting in progressive organ damage.
DISCUSSION
We reviewed published literature between January 1st, 2000 and June 30th, 2020, excluding articles focusing on pediatric or obstetric population, with a focus on virus-host interactions and immunological mechanisms responsible for virus associated cytokine release syndrome (CRS). COVID-19 illness encompasses three main phases. In phase 1, SARS-CoV-2 binds with angiotensin converting enzyme (ACE)2 receptor on alveolar macrophages and epithelial cells, triggering toll like receptor (TLR) mediated nuclear factor kappa-light-chain-enhancer of activated B cells (NF-ƙB) signaling. It effectively blunts an early (IFN) response allowing unchecked viral replication. Phase 2 is characterized by hypoxia and innate immunity mediated pneumocyte damage as well as capillary leak. Some patients further progress to phase 3 characterized by cytokine storm with worsening respiratory symptoms, persistent fever, and hemodynamic instability. Important cytokines involved in this phase are interleukin (IL)-6, IL-1β, and tumor necrosis factor (TNF)-α. This is typically followed by a recovery phase with production of antibodies against the virus. We summarize published data regarding virus-host interactions, key immunological mechanisms responsible for virus-associated CRS, and potential opportunities for therapeutic interventions.
CONCLUSION
Evidence regarding SARS-CoV-2 epidemiology and pathogenesis is rapidly evolving. A better understanding of the pathophysiology and immune system dysregulation associated with CRS and acute respiratory distress syndrome in severe COVID-19 is imperative to identify novel drug targets and other therapeutic interventions.
Identifiants
pubmed: 33059711
doi: 10.1186/s12985-020-01415-w
pii: 10.1186/s12985-020-01415-w
pmc: PMC7558250
doi:
Substances chimiques
Antiviral Agents
0
Cytokines
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
154Références
Am J Pathol. 2016 Mar;186(3):630-8
pubmed: 26724387
Emerg Microbes Infect. 2020 Dec;9(1):221-236
pubmed: 31987001
Euro Surveill. 2020 Apr;25(16):
pubmed: 32347204
Inflammation. 2014 Dec;37(6):2091-8
pubmed: 24912813
Virol J. 2005 Aug 22;2:69
pubmed: 16115318
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Nature. 2020 Mar;579(7798):270-273
pubmed: 32015507
Int J Infect Dis. 2020 May;94:154-155
pubmed: 32179137
J Infect Dev Ctries. 2020 Feb 29;14(2):125-128
pubmed: 32146445
Cell Rep. 2020 Jul 7;32(1):107863
pubmed: 32610043
N Engl J Med. 2020 May 7;382(19):1787-1799
pubmed: 32187464
J Virol. 2014 Jan;88(2):1293-307
pubmed: 24227843
Cell. 2008 Apr 18;133(2):235-49
pubmed: 18423196
Immunotherapy. 2019 Jul;11(10):851-857
pubmed: 31161844
Proc Natl Acad Sci U S A. 2009 Jan 13;106(2):582-7
pubmed: 19124777
Prog Cardiovasc Dis. 2020 May - Jun;63(3):390-391
pubmed: 32169400
J Med Virol. 2020 Jun;92(6):602-611
pubmed: 32104911
Pharmacol Ther. 2020 May;209:107512
pubmed: 32097670
Cell Res. 2020 Mar;30(3):269-271
pubmed: 32020029
Antivir Chem Chemother. 2006;17(5):275-84
pubmed: 17176632
Antiviral Res. 2020 May;177:104762
pubmed: 32147496
Am J Clin Pathol. 2004 Apr;121(4):507-11
pubmed: 15080302
PLoS Med. 2006 Sep;3(9):e343
pubmed: 16968120
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
mBio. 2015 May 26;6(3):e00638-15
pubmed: 26015500
Virology. 2015 Nov;485:330-9
pubmed: 26331680
Engineering (Beijing). 2020 Oct;6(10):1192-1198
pubmed: 32346491
N Engl J Med. 2020 Sep 3;383(10):994
pubmed: 32649078
Clin Infect Dis. 2020 Jul 28;71(15):762-768
pubmed: 32161940
J Exp Med. 2005 Aug 1;202(3):415-24
pubmed: 16043521
J Virol. 2017 Sep 27;91(20):
pubmed: 28794018
JAMA. 2020 Apr 28;323(16):1582-1589
pubmed: 32219428
J Infect. 2004 Nov;49(4):262-73
pubmed: 15474623
mBio. 2018 Oct 9;9(5):
pubmed: 30301856
Viral Immunol. 2012 Oct;25(5):347
pubmed: 23035850
J Med Virol. 2020 Jun;92(6):667-674
pubmed: 32167180
Science. 2020 Aug 7;369(6504):712-717
pubmed: 32527928
Intensive Care Med. 2020 Apr;46(4):586-590
pubmed: 32125455
Intensive Care Med. 2020 May;46(5):846-848
pubmed: 32125452
Lancet. 2020 Mar 28;395(10229):1014-1015
pubmed: 32197108
Pathogens. 2020 Mar 04;9(3):
pubmed: 32143502
Biotechnol Rep (Amst). 2020 May 14;26:e00467
pubmed: 32420049
Eur J Pharmacol. 2018 Jul 15;831:68-76
pubmed: 29715453
J Immunol. 2008 Jan 15;180(2):683-7
pubmed: 18178804
Science. 2020 Aug 7;369(6504):706-712
pubmed: 32527925
JAMA. 2020 Jul 14;324(2):168-177
pubmed: 32558877
Lancet Infect Dis. 2020 Apr;20(4):400-402
pubmed: 32113509
J Clin Med. 2020 Feb 17;9(2):
pubmed: 32079150
Am J Obstet Gynecol MFM. 2020 Aug;2(3):100145
pubmed: 32427221
Clin Ophthalmol. 2012;6:377-83
pubmed: 22457587
Front Immunol. 2019 Jan 31;10:55
pubmed: 30766533
Natl Sci Rev. 2020 Jun;7(6):1012-1023
pubmed: 34676127
Zhonghua Liu Xing Bing Xue Za Zhi. 2020 Feb 10;41(2):145-151
pubmed: 32064853
Immunity. 2020 May 19;52(5):731-733
pubmed: 32325025
Proc Natl Acad Sci U S A. 2020 May 19;117(20):10970-10975
pubmed: 32350134
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Crit Care Med. 2016 Feb;44(2):275-81
pubmed: 26584195
Crit Care. 2020 Mar 16;24(1):91
pubmed: 32178711
Int J Mol Sci. 2019 Jul 10;20(14):
pubmed: 31295952
Int J Antimicrob Agents. 2020 Apr;55(4):105932
pubmed: 32145363
Lancet. 2020 Feb 15;395(10223):473-475
pubmed: 32043983
JAMA. 2020 Apr 28;323(16):1610-1612
pubmed: 32129805
Emerg Infect Dis. 2020 Jul;26(7):1478-1488
pubmed: 32267220
Nat Rev Clin Oncol. 2018 Jan;15(1):47-62
pubmed: 28925994
Proc Jpn Acad Ser B Phys Biol Sci. 2017;93(7):449-463
pubmed: 28769016
Cell Biochem Funct. 2016 Jun;34(4):191-6
pubmed: 27001679
Dermatologica. 1989;178(1):39-42
pubmed: 2917679
Drugs. 2019 Aug;79(12):1355-1361
pubmed: 31313098
Cell. 2020 May 28;181(5):1036-1045.e9
pubmed: 32416070
J Immunol. 2000 Aug 1;165(3):1534-40
pubmed: 10903761
Stem Cell Rev Rep. 2020 Jun;16(3):427-433
pubmed: 32281052
Travel Med Infect Dis. 2020 Mar - Apr;34:101615
pubmed: 32145386
Lancet. 2020 Mar 28;395(10229):1033-1034
pubmed: 32192578
Crit Care. 2017 Dec 13;21(1):305
pubmed: 29237475
JAMA. 2020 May 12;323(18):1843-1844
pubmed: 32159775
Cell. 2020 Apr 16;181(2):271-280.e8
pubmed: 32142651
Clin Infect Dis. 2020 Jun 16;:
pubmed: 32556191
Cell Host Microbe. 2020 Jun 10;27(6):992-1000.e3
pubmed: 32320677
Lancet Infect Dis. 2003 Nov;3(11):722-7
pubmed: 14592603
Nature. 2020 Jul;583(7816):469-472
pubmed: 32408336
J Med Virol. 2020 Apr;92(4):424-432
pubmed: 31981224
Cell. 2020 May 14;181(4):905-913.e7
pubmed: 32333836
Intensive Care Med. 2020 Apr;46(4):579-582
pubmed: 32103284
Am J Respir Crit Care Med. 2018 Mar 15;197(6):757-767
pubmed: 29161116
Biosci Rep. 2018 Apr 27;38(2):
pubmed: 29531017
Emerg Microbes Infect. 2020 Dec;9(1):747-756
pubmed: 32196430
Nat Med. 2020 Apr;26(4):502-505
pubmed: 32284613
Int J Antimicrob Agents. 2020 Jul;56(1):105949
pubmed: 32205204
Science. 2020 Sep 4;369(6508):1249-1255
pubmed: 32680882
Emerg Infect Dis. 2020 Jun;26(6):1339-1441
pubmed: 32168463
PLoS One. 2019 Sep 27;14(9):e0222944
pubmed: 31560729